Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wilson
Anne Scheinberg

Showing results (101-110 of 181) with videos related to

Pageof 19
Sort By:
Pediatrics|September 11, 2013
The rising incidence of celiac disease in ScotlandLois E White, Victoria M Merrick, Elaine Bannerman, et al.
Archives of Disease in Childhood|October 9, 2017
Biosimilar infliximab use in paediatric IBDLisa Richmond, Lee Curtis, Victoria Garrick, et al.
Biologics : Targets & Therapy|May 5, 2025
Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort StudySilvana Ancona, Katherine Armstrong, Chiara Longo, et al.
The Journal of Pediatrics|February 14, 2003
Glucose intolerance in children with cystic fibrosisMelinda P Solomon, David C Wilson, Mary Corey, et al.
Journal of Pediatric Gastroenterology and Nutrition|May 19, 2006
6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experienceMadhur Ravikumara, Frank G H Hill, David C Wilson, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 27, 2007
Natalizumab therapy for moderate to severe Crohn disease in adolescentsJeffrey S Hyams, David C Wilson, Adrian Thomas, et al.
The British Journal of Nutrition|December 16, 2016
5-Hydroxyvitamin D concentration in paediatric cancer patients from Scotland: a prospective cohort studyRaquel Revuelta Iniesta, Ilenia Paciarotti, Isobel Davidson, et al.
Gut|June 12, 2012
The intermediate filament protein, vimentin, is a regulator of NOD2 activityCraig Stevens, Paul Henderson, Elaine R Nimmo, et al.
Gut|May 25, 2013
Paneth cell marker CD24 in NOD2 knockout organoids and in inflammatory bowel disease (IBD)Johan Van Limbergen, Kaoru Geddes, Paul Henderson, et al.
Journal of Pediatric Gastroenterology and Nutrition|September 23, 2016
Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel DiseaseFiona L Cameron, Mabrouka A Altowati, Pamela Rogers, et al.
Pageof 19

Showing results (101-110 of 181) with videos related to

Sort By:
Pageof 19
Pediatrics|September 11, 2013
The rising incidence of celiac disease in ScotlandLois E White, Victoria M Merrick, Elaine Bannerman, et al.
Archives of Disease in Childhood|October 9, 2017
Biosimilar infliximab use in paediatric IBDLisa Richmond, Lee Curtis, Victoria Garrick, et al.
Biologics : Targets & Therapy|May 5, 2025
Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort StudySilvana Ancona, Katherine Armstrong, Chiara Longo, et al.
The Journal of Pediatrics|February 14, 2003
Glucose intolerance in children with cystic fibrosisMelinda P Solomon, David C Wilson, Mary Corey, et al.
Journal of Pediatric Gastroenterology and Nutrition|May 19, 2006
6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experienceMadhur Ravikumara, Frank G H Hill, David C Wilson, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 27, 2007
Natalizumab therapy for moderate to severe Crohn disease in adolescentsJeffrey S Hyams, David C Wilson, Adrian Thomas, et al.
The British Journal of Nutrition|December 16, 2016
5-Hydroxyvitamin D concentration in paediatric cancer patients from Scotland: a prospective cohort studyRaquel Revuelta Iniesta, Ilenia Paciarotti, Isobel Davidson, et al.
Gut|June 12, 2012
The intermediate filament protein, vimentin, is a regulator of NOD2 activityCraig Stevens, Paul Henderson, Elaine R Nimmo, et al.
Gut|May 25, 2013
Paneth cell marker CD24 in NOD2 knockout organoids and in inflammatory bowel disease (IBD)Johan Van Limbergen, Kaoru Geddes, Paul Henderson, et al.
Journal of Pediatric Gastroenterology and Nutrition|September 23, 2016
Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel DiseaseFiona L Cameron, Mabrouka A Altowati, Pamela Rogers, et al.
Pageof 19